Elvina Almuradova· @Dr_ElvinaA · X·· 22 小时前评分45
正文 · 原文
Selective CDK4 inhibition in endocrine-resistant #BreastCancer: phase 2 results for atirmociclib + fulvestrant, an Oral Abstract Session at #ESMO26 @OncoAlert @Larvol
161 浏览 · 6 赞 · 5 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com